Handelsbanken Fonder’s Viking Therapeutics VKTX Stock Holding History

Handelsbanken Fonder’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69M	Buy	43,400 +7,700	+22%	+$249K	﹤0.01%	888
2026 Q1	$1.16M	Hold	35,700	–	–	﹤0.01%	974
2025 Q4	$1.26M	Sell	35,700 -1,600	-4%	-$56.7K	﹤0.01%	943
2025 Q3	$980K	Buy	37,300 +5,200	+16%	+$155K	﹤0.01%	1009
2025 Q2	$851K	Sell	32,100 -3,700	-10%	-$97.4K	﹤0.01%	1034
2025 Q1	$865K	Sell	35,800 -147,600	-80%	-$4.66M	﹤0.01%	996
2024 Q4	$7.38M	Buy	183,400 +3,400	+2%	+$194K	0.03%	394
2024 Q3	$11.4M	Buy	180,000 +158,100	+722%	+$9.28M	0.05%	329
2024 Q2	$1.16M	Sell	21,900 -6,400	-23%	-$420K	0.01%	775
2024 Q1	$2.32M	Buy	28,300 +5,600	+25%	+$249K	0.01%	566
2023 Q4	$422K	Buy	22,700 +7,300	+47%	+$95.5K	﹤0.01%	1227
2023 Q3	$170K	Hold	15,400	–	–	﹤0.01%	1502
2023 Q2	$250K	Buy	+15,400	New	+$323K	﹤0.01%	1418

Other funds holding VKTX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Handelsbanken Fonder's VKTX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Viking Therapeutics (VKTX) stake by 22% in Q2 2026, buying an estimated $249K and bringing the position to 43,400 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Handelsbanken Fonder first reported a position in VKTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $11.4M in Q3 2024. 172 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Handelsbanken Fonder held 43,400 shares of Viking Therapeutics worth $1.69M as of Q2 2026.
Handelsbanken Fonder bought 7,700 Viking Therapeutics shares in Q2 2026, an estimated $249K.
Viking Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #888 holding.
Handelsbanken Fonder first reported a position in Viking Therapeutics in Q2 2023 and has held it in 13 quarters since.
Handelsbanken Fonder's Viking Therapeutics position peaked at $11.4M in Q3 2024.
172 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.